Dear Member,

Thank you for inviting me to be part of your care, and welcome—to you and to your treating physicians who requested this consultation—for a comprehensive second opinion. I have carefully reviewed the records provided and our discussion. My goal is to synthesize your clinical history and test results, answer your key questions, and outline a renal- and transplant-safe plan that can be implemented in close coordination with your care team. The recommendations that follow are intended to support (not replace) your ongoing treatment; please review them with your transplant cardiology, nephrology, neurology, orthopedics, PM&R, and PT/OT clinicians so we remain fully aligned on next steps.

Virtual Neurology Second Opinion Consultation

Consultation Date:

Member Name:

DOB / Age:

Gender:

Case Number:

Referring Physician (if any):

Provider: Dr. Nizar Souayah, MD, FAAN, FAANEM, FANA

Visit Type: Virtual Neurological Examination (Telemedicine)

Platform Used: [☐ Zoom ☐ Doxy.me ☐ Other: _____]

Location of Member: _____

Location of Physician: _____

1. Reason for Consultation

The member is a 46-year-old male with multifactorial neuropathy that developed after a December 2023 orthotopic heart transplant, now presenting with persistent distal numbness, burning, and electric-shock sensations in both feet. Symptoms have been refractory to low-dose gabapentin (200 mg qHS) and formal PT (paused after a May 2025 left ankle fracture with consequent mobility limits). He seeks an educational, second-opinion consult to (1) clarify the etiology of his neuropathy in the context of diabetes, ESRD on hemodialysis, critical illness, and a superimposed lumbosacral

plexopathy on EMG; (2) review prior diagnostics (EMG/NCS, labs) and identify additional, transplant-/renal-safe testing; (3) optimize neuropathic pain management and orthotic/DME needs (AFO) to reduce falls; and (4) establish a staged rehabilitation plan and SMART goals (≥30% pain reduction at 8–12 weeks; safe stand-pivot transfers by week 6; AFO-assisted gait initiation by week 8, ortho clearance permitting).

The member asked the following five questions :

Etiology/Mechanism: Which factors best explain his mixed pattern of length-dependent sensory loss and asymmetric proximal weakness, and how do they interact?

Diagnostic Next Steps: What renal- and transplant-compatible tests should be prioritized now how will each result change management?

Medication Optimization: Given subtherapeutic gabapentin, what is the safest, evidence-based analgesic strategy and what monitoring is needed for side effects and tacrolimus interactions?

Function & Safety: Which orthotics/DME and PT/OT milestones will most effectively reduce falls, protect skin integrity, and restore mobility after the ankle fracture?

Care Coordination & Follow-up: What multidisciplinary cadence (neurology, transplant, nephrology, PT/OT) and time-bound outcomes should be used over the next 4–12 weeks, and which red-flags warrant urgent escalation ?2. Summary of Medical

2. Records Reviewed

The available records depict a medically complex, 46-year-old right-handed man whose neuropathic syndrome emerged after a December 2023 orthotopic heart transplant and evolved on the background of end-stage renal disease on hemodialysis, type 2 diabetes, prolonged critical illness, and multiple infectious/surgical complications, producing a coherent but multifactorial picture that explains both his length-dependent distal sensory loss and his asymmetric proximal weakness with superimposed right lumbosacral plexopathy. Hospital documents outline an initial course of cardiogenic shock and anterior STEMI with cardiac arrest requiring resuscitation, mechanical circulatory support, and transplantation, followed by an extended ICU stay complicated by recurrent Serratia bacteremia (with disseminated infections including empyema and sternal wound infection), repeated line placements, tracheostomy with later decannulation, and extensive wound care with muscle/skin flap procedures; together, this cluster of exposures is classic for critical-illness polyneuropathy/myopathy and establishes biological plausibility for diffuse axonal damage and global deconditioning. Beginning in early 2024 he developed progressive distal numbness, burning and electric-shock dysesthesias in both feet, then sensory ataxia, and subsequently asymmetric proximal weakness (right greater than left) and a left foot-drop requiring orthosis and cane use prior to a left ankle fracture in May 2025 that precipitated wheelchair dependence; importantly, he denies upper-extremity or cranial neuropathic symptoms, and aside from orthostatic fluctuations attributable to renal failure and antihypertensive regimens he has no report of autonomic crises. The most informative objective study is the February 2025 EMG/NCS,

which demonstrates a severe chronic axonal sensorimotor polyneuropathy with superimposed subacute-to-early chronic right lumbosacral plexopathy—exactly the combination anticipated from diabetes, uremia, and critical illness layered with a regional plexus process that accounts for the observed asymmetry and proximal weakness; this electrophysiologic pattern triangulates well with the bedside examination showing global areflexia, distal gradient sensory loss to mid-calf on pin and vibration, intact finger-to-nose, heel-to-shin limited by weakness, 4/5 strength at hip/knee bilaterally, 0/5 ankle dorsiflexion and 3/5 plantarflexion, and unassessable gait in the context of fracture and wheelchair use. Complementary studies include a cardiac assessment revealing reduced left ventricular ejection fraction at 30–35% with mild–moderate tricuspid regurgitation but no acute rejection, and orthopedic imaging confirming a closed left ankle fracture; prior neuroimaging mentioned a possible subarachnoid hemorrhage early in 2024 that has since had no ongoing clinical correlate. Longitudinal labs from December 2024 through June 2025 exclude B12 deficiency and thyroid dysfunction and document diabetes control with an A1c of 6.9% (October 2024), though micronutrient testing for thiamine, copper, and vitamin E is not recorded and would be germane given his prolonged illness, dialysis, prior infections, and nutritional risk. Medication history is detailed and clinically consequential: tacrolimus (target trough 6–8 ng/mL) and low-dose prednisone for immunosuppression, gabapentin 200 mg nightly with minimal benefit for neuropathic pain, heart-failure and lipid therapies (carvedilol, valsartan, atorvastatin, aspirin, ezetimibe), lifelong levofloxacin, and vitamin D with a multivitamin; this regimen underscores two actionable points—the current gabapentin dose is subtherapeutic in general and especially inadequate for severe axonal polyneuropathy, and tacrolimus neurotoxicity, while uncommon as a cause of length-dependent peripheral neuropathy, still warrants periodic correlation of symptom fluctuations with trough levels to exclude exposure-related effects. Past surgical and infectious records—tracheostomy with decannulation, multiple debridements and flap closures, thromboendarterectomy with bovine patch angioplasty, AV fistula creation and revisions, and toe amputations in November 2024 for osteomyelitis—explain deconditioning, persistent wound-care needs, and the limb biomechanical stressors that magnify fall and ulcer risk in the setting of distal sensory loss and foot-drop. Family history (maternal heart disease/diabetes, paternal colon cancer, a brother with type 2 diabetes) and a social history notable for living with a spouse and absence of tobacco, alcohol, or illicit drugs add context but do not suggest hereditary neuropathy; no genetic testing has been performed, appropriate given the dominant acquired drivers. Several inconsistencies and documentation gaps merit emphasis because they influence next steps: the patient describes intermittent “shooting” pains more than constant burning—still compatible with axonal neuropathy but a cue to evaluate focal generators and optimize topical therapies; despite severe length-dependent disease there is no reported upper-extremity involvement, which is not implausible at this stage but should be trended with repeat EMG that includes upper limbs; crucially, there is no MRI neurography of the lumbosacral plexus to anatomically define the EMG-proven plexopathy and exclude structural, ischemic, or inflammatory causes; no repeat EMG with F-waves/H-reflex since February 2025 is documented to quantify progression or clarify proximal conduction abnormalities; micronutrient/inflammatory/autoimmune panels (thiamine, copper, vitamin E, ESR/CRP ± SSA/SSB/ANCA/complements when clinically indicated) are not recorded; CSF analysis has not been pursued—appropriately deferred unless the course becomes atypical or rapidly progressive; and rehabilitation/DME specifics (custom AFO specifications, PT/OT dosing

aligned to dialysis, fall/near-miss and skin-check logs) are missing despite clear medical necessity. When these findings are integrated, the parsimonious diagnosis is a severe chronic axonal sensorimotor polyneuropathy driven by diabetes, uremia, and prior critical illness, compounded by a right-sided lumbosacral plexopathy that explains the asymmetric proximal weakness and functional decline; the fracture and historical toe amputations delineate a high-stakes safety profile where fall prevention, pressure-injury avoidance, and infection surveillance are as important as analgesia. The records therefore support a targeted, transplant- and renal-safe plan: repeat EMG/NCS including upper limbs with F-waves/H-reflex and MRI neurography of the lumbosacral plexus within 0–2 weeks to anatomically and physiologically stage the plexus lesion; obtain focused labs for nutritional and inflammatory contributors on non-dialysis days; review tacrolimus troughs against symptom diaries; transition from subtherapeutic gabapentin to renal-adjusted pregabalin with topical lidocaine (and clinic capsaicin for focal allodynia) while avoiding duloxetine unless nephrology deems a very low-dose trial acceptable; and implement structured PT/OT with dialysis-aware scheduling, custom AFO and off-loading, and SMART outcomes (≥30% pain reduction by 8–12 weeks, safe stand-pivot transfers by week 6, AFO-assisted gait initiation by week 8 as orthopedically allowed, 0 injurious falls, and no new skin breakdown). Finally, the documentation makes a strong payer-facing case for medical necessity: EMG-confirmed polyneuropathy with lumbosacral plexopathy causing foot-drop, falls, and refractory pain justifies custom AFO, structured therapy, repeat electrodiagnostics, and plexus MRI, all coordinated across neurology, transplant cardiology, nephrology, orthopedics, and PM&R, with clear red-flag pathways (rapid asymmetric decline, sphincter changes, febrile wound drainage, sudden gait collapse) for urgent escalation.

3. History of Present Illness (HPI)

(Detailed chronological narrative of symptom onset, progression, prior treatments, responses, exacerbating/relieving factors, and current impact on function and quality of life.)

4. Past Medical, Surgical, Family, and Social History

A. Past Medical History:

His past medical history includes ischemic cardiomyopathy complicated by cardiac arrest necessitating heart transplantation; end-stage renal disease on hemodialysis with multiple fistula revisions and ongoing kidney transplant evaluation; type 2 diabetes mellitus (A1c 6.9% in October 2024); hyperlipidemia managed with statins and ezetimibe; hypogammaglobulinemia requiring monthly IVIG; recurrent Serratia bacteremia with empyema, sternal wound infection, and groin hematoma; subacute osteomyelitis of the left foot leading to toe amputations in November 2024; and hypertension, previously complicated by orthostatic hypotension.

B. Past Surgical History:

His past surgical history is extensive and includes the heart transplant, tracheostomy with later decannulation, multiple debridements and flap procedures for wound healing,

thromboendarterectomy with bovine patch angioplasty, toe amputations, and AV fistula creation and revisions.

C. Family History:

Family history is significant for maternal heart disease and diabetes, paternal colon cancer, and a brother with type 2 diabetes.

D. Social History:

He lives with his spouse, denies tobacco, alcohol, or illicit drug use, and is currently wheelchair-bound due to combined neuropathic deficits and orthopedic restrictions.

5. Medications and Allergies

Current medications include tacrolimus (goal trough 6–8 ng/mL) and prednisone 5 mg daily for immunosuppression; gabapentin 200 mg nightly for neuropathic symptoms (with minimal reported benefit); carvedilol, valsartan, atorvastatin, aspirin, and ezetimibe for cardiovascular management; lifelong levofloxacin for infectious prophylaxis; and vitamin D with a multivitamin.

6. Review of Systems (ROS)

General:

☐ No fevers ☐ No chills ☐ No weight loss ☐ Fatigue ☐ Night sweats

Comments: _____

Neurological:

☐ Headaches ☐ Dizziness ☐ Seizures ☐ Memory loss ☐ Numbness/tingling ☐ Weakness ☐ Tremor ☐ Falls ☐ Imbalance ☐ Speech difficulty ☐ Vision changes ☐ Hearing changes ☐ Swallowing difficulty

Comments: _lower extremity numbness, paresthesias, foot drop, and gait imbalance_____

Psychiatric / Cognitive:

☐ Normal mood ☐ Depression ☐ Anxiety ☐ Sleep disturbance ☐ Hallucinations ☐ Cognitive decline

Comments: _____

HEENT:

☐ Vision loss ☐ Blurred vision ☐ Diplopia ☐ Hearing loss ☐ Tinnitus ☐ Vertigo ☐ Sinus pain ☐ Sore throat ☐ Dysphonia

Comments: _____

Cardiovascular:

☐ Chest pain ☐ Palpitations ☐ Syncope ☐ Orthopnea ☐ Dyspnea on exertion ☐ Leg swelling

Comments: _____

Respiratory:

☐ Cough ☐ Shortness of breath ☐ Wheezing ☐ Sleep apnea ☐ Orthopnea ☐ Ventilator/CPAP use

Comments: _____

Gastrointestinal:

☐ Nausea ☐ Vomiting ☐ Abdominal pain ☐ Constipation ☐ Diarrhea ☐ Dysphagia ☐ GERD ☐ GI bleeding

Comments: _____

Genitourinary:

☐ Dysuria ☐ Frequency ☐ Urgency ☐ Retention ☐ Incontinence ☐ Sexual dysfunction

Comments: _____

Musculoskeletal:

☐ Myalgia ☐ Arthralgia ☐ Joint swelling ☐ Muscle cramps ☐ Stiffness ☐ Limited mobility

Comments: _____

Skin:

☐ Rash ☐ Ulcers ☐ Photosensitivity ☐ Skin changes ☐ Bruising

Comments: _____

Endocrine / Metabolic:

☐ Heat intolerance ☐ Cold intolerance ☐ Polyuria ☐ Polydipsia ☐ Weight changes ☐ Thyroid disorder ☐ Diabetes

Comments: _____

Hematologic / Immunologic:

☐ Easy bruising ☐ Bleeding ☐ Anemia ☐ Frequent infections ☐ Autoimmune disease

Comments: _____

7. Virtual Neurological Examination

I. General & Technical Information

Consent obtained: [☐ Yes ☐ No]

Audio/Video Quality: [☐ Excellent ☐ Good ☐ Fair ☐ Poor]

Chaperone present: [☐ Yes ☐ No]

Limitations due to virtual format: [☐ Reflexes ☐ Tone ☐ Fundoscopy ☐ Detailed sensory testing ☐ Other: _____]

II. General Observation / Mental Status

Level of consciousness: [☐ Alert ☐ Drowsy ☐ Confused ☐ Unresponsive]

Orientation: [☐ Person ☐ Place ☐ Time ☐ Situation]

Appearance: [☐ Normal ☐ Disheveled ☐ Neglected hygiene ☐ Other: _____]

Speech: [☐ Normal fluency ☐ Dysarthric ☐ Aphasic ☐ Slurred]

Language comprehension: [☐ Intact ☐ Impaired]

Attention: [☐ Normal ☐ Reduced]

Memory: [☐ Intact ☐ Impaired immediate recall ☐ Impaired delayed recall]

III. Cranial Nerves

CN I (Olfactory): [☐ Not tested ☐ Reports anosmia ☐ Normal]

CN II: [☐ Visual fields intact ☐ Visual field defect ☐ Reduced acuity]

CN III, IV, VI: [☐ Full EOM ☐ Nystagmus ☐ Ptosis ☐ Limited movement]

CN V: [☐ Symmetric ☐ Numbness ☐ Masseter intact]

CN VII: [☐ Symmetric ☐ R weakness ☐ L weakness]

CN VIII: [☐ Intact ☐ Reduced hearing ☐ Tinnitus ☐ Balance symptoms]

CN IX, X: [☐ Voice normal ☐ Dysarthria ☐ Dysphonia ☐ Swallow difficulty]

CN XI: [☐ Symmetric ☐ Weakness present]

CN XII: [☐ Midline ☐ Deviates ☐ Fasciculations]

IV. Motor Examination (Expanded for Virtual Evaluation)

Bulk:

[☐ Normal ☐ Atrophy noted (site: _____) ☐ Fasciculations observed ☐ Asymmetry present]

Tone:

[☐ Appears normal (visual inspection and passive movement via patient self-demonstration) ☐ Cannot be fully assessed due to virtual limitations]

Strength (Functional Assessment via Tasks):

Upper Extremities

Shoulder abduction: [☐ Normal ☐ Weakness R ☐ Weakness L]

Elbow flexion/extension: [☐ Normal ☐ Weakness R ☐ Weakness L]

Wrist extension/flexion: [☐ Normal ☐ Weakness R ☐ Weakness L]

Grip strength (squeeze object, e.g., water bottle): [☐ Normal ☐ Weakness R ☐ Weakness L]

Lower Extremities

Hip flexion: [☐ Normal ☐ Weakness R ☐ Weakness L]

Knee extension/flexion: [☐ Normal ☐ Weakness R ☐ Weakness L]

Ankle dorsiflexion/plantarflexion: [☐ Normal ☐ Weakness R ☐ Weakness L]

Drift (Barre/Raimiste test):

[☐ No drift ☐ Right drift ☐ Left drift ☐ Pronator drift with downward drift/pronation]

Fine Motor Movements:

Finger tapping: [☐ Normal ☐ Slowed ☐ Irregular ☐ Asymmetric]

Rapid alternating movements (RAMs): [☐ Normal ☐ Bradykinetic ☐ Irregular]

Toe tapping: [☐ Normal ☐ Slowed ☐ Asymmetric]

Functional Observations:

Ability to rise from chair without hands: [☐ Yes ☐ Requires hands ☐ Unable]

Ability to stand from squatting: [☐ Yes ☐ No ☐ With difficulty]

Arm swing during gait: [☐ Symmetric ☐ Reduced R ☐ Reduced L ☐ Absent]

Endurance/fatigability: [☐ No early fatigue ☐ Fatigue on repeated effort ☐ Unable to sustain posture (site: _____)]

V. Coordination

Finger-to-nose: [☐ Normal ☐ Dysmetria R ☐ Dysmetria L]

RAMs: [☐ Normal ☐ Bradykinetic ☐ Irregular]

Heel-to-shin: [☐ Normal ☐ Ataxic R ☐ Ataxic L]

VI. Gait & Station

Gait: [☐ Normal ☐ Antalgic ☐ Ataxic ☐ Spastic ☐ Parkinsonian ☐ Wide-based]

Heel/Toe walk: [☐ Normal ☐ Unable ☐ Unsteady]

Tandem gait: [☐ Normal ☐ Abnormal]

Romberg: [☐ Negative ☐ Positive]

VII. Sensory Examination

Light touch: [☐ Symmetric ☐ Numbness R ☐ Numbness L]

Pain: [☐ Symmetric ☐ Reduced R ☐ Reduced L]

Proprioception/Vibration (by history): [☐ Intact ☐ Difficulty reported]

VIII. Reflexes

Deferred (virtual limitation). Documented: [☐ Yes]

IX. Special Tests (if applicable — Neuromuscular Expanded)

Stroke / Cerebrovascular Screen:

Facial symmetry: [☐ Symmetric ☐ Right droop ☐ Left droop]

Arm strength/drift: [☐ No drift ☐ Right ☐ Left]

Speech: [☐ Normal ☐ Dysarthric ☐ Aphasic ☐ Slurred]

Tremor / Movement Disorders:

Tremor: [☐ None ☐ Resting ☐ Postural ☐ Action ☐ Intention]

Bradykinesia: [☐ Absent ☐ Present]

Freezing of gait: [☐ Absent ☐ Present]

Myasthenia Gravis:

Sustained upgaze: [☐ Normal ☐ Ptosis after ___ sec]

Speech endurance: [☐ Stable ☐ Dysarthria with fatigue]

Counting on single breath: [☐ >20 ☐ 10–20 ☐ <10]

Lambert-Eaton Myasthenic Syndrome:

Sit-to-stand endurance: [☐ Normal ☐ Strength improves ☐ Strength declines]

Autonomic features: [☐ Dry mouth ☐ Constipation]

ALS / Motor Neuron Disease:

Fasciculations: [☐ None ☐ Present (site: ___)]

Atrophy: [☐ Absent ☐ Present (location: ___)]

Bulbar signs: [☐ Dysarthria ☐ Dysphagia]

Peripheral Neuropathies (CIDP/GBS/hereditary):

Distal weakness: [☐ None ☐ Foot drop ☐ Hand weakness]

Sensory loss: [☐ Stocking ☐ Glove ☐ Asymmetric]

Romberg: [☐ Negative ☐ Positive]

Muscular Dystrophies / Myopathies:

Scapular winging: [☐ Absent ☐ Present]

Facial weakness: [☐ Absent ☐ Present]

Gowers' sign: [☐ Absent ☐ Present]

Myotonia: [☐ Absent ☐ Present]

Metabolic / Mitochondrial Myopathies:

Exercise intolerance: [☐ Absent ☐ Present]

Ocular involvement: [☐ None ☐ Ptosis ☐ Ophthalmoplegia]

Inflammatory Myopathies (PM/DM/IBM):

Proximal weakness: [☐ Absent ☐ Present]

Skin rash: [☐ None ☐ Heliotrope ☐ Gottron's papules]

Asymmetry (IBM): [☐ Absent ☐ Present]

Channelopathies:

Periodic paralysis episodes: [☐ Absent ☐ HypoK ☐ HyperK]

Cold-induced myotonia: [☐ Absent ☐ Present]

Autonomic Dysfunction:

Orthostatic intolerance: [☐ Absent ☐ Present]

Bladder dysfunction: [☐ None ☐ Urgency ☐ Retention]

Sweating abnormalities: [☐ None ☐ Reduced ☐ Excessive]

Respiratory Involvement:

Dyspnea: [☐ None ☐ On exertion ☐ At rest ☐ Orthopnea]

Cough strength: [☐ Normal ☐ Weak]

Ventilatory support: [☐ None ☐ CPAP ☐ BiPAP ☐ Ventilator]

In summary: On examination, he is alert and cooperative, afebrile, cranial nerves are intact; upper extremity strength is 5/5; hip and knee flexion are 4/5 bilaterally; foot dorsiflexion is 0/0 and plantarflexion 3/3; reflexes are absent throughout (per medical records) ; sensory testing reveals decreased pinprick and vibration in toes and ankles with deficits extending proximally to mid-calf (as per medical records), contributing to proprioceptive imbalance; finger-to-nose coordination is intact, but heel-to-shin testing is limited by weakness; and gait is not assessable due to fracture and wheelchair dependence.

8. Assessment / Differential Diagnosis

Based on the review of medical records and the videoconference evaluation, I recommended that the member discuss with his treating providers the following differential diagnoses and potential ancillary tests:

The member's neuropathy is complex and likely multifactorial. Based on the history of orthotopic heart transplantation, prolonged ICU stay, ESRD on dialysis, type 2 diabetes mellitus, multiple infections, and EMG findings showing severe chronic axonal sensorimotor polyneuropathy with superimposed lumbosacral plexopathy, the following differential diagnoses should be considered:

- Diabetic Polyneuropathy (Axonal, Length-Dependent):

Rationale: Member has long-standing type 2 diabetes; typical pattern is distal symmetric sensory loss and burning dysesthesias beginning in the feet.

Supportive findings: Length-dependent sensory loss, EMG showing chronic axonal pattern, diabetic control history.

Limitations: Does not explain asymmetric proximal weakness or plexopathy findings.

- Uremic Neuropathy (ESRD-related):

Rationale: ESRD on chronic hemodialysis predisposes to slowly progressive symmetric sensorimotor neuropathy due to uremic toxins and metabolic imbalance.

Supportive findings: Polyneuropathy pattern, ESRD history.

Limitations: Superimposed focal findings suggest an additional etiology.

- Critical Illness Polyneuropathy/Myopathy:

Rationale: Prolonged ICU stay, sepsis, mechanical ventilation, and multiorgan failure strongly predispose to critical illness neuropathy/myopathy.

Supportive findings: Diffuse weakness, absent reflexes, sensory and motor axonal loss on EMG.

Limitations: Typically diffuse and symmetric; does not account fully for lumbosacral plexopathy.

- Lumbosacral Plexopathy (Ischemic/Inflammatory):

Rationale: EMG suggests superimposed plexopathy; possible etiologies include vascular injury from central line procedures, ischemic insult, or immune-mediated plexitis.

Supportive findings: Asymmetric proximal weakness (right > left thigh), plexopathy on EMG.

- Medication-Induced Neurotoxicity (Tacrolimus):

Rationale: Tacrolimus can rarely cause neurotoxicity including neuropathy and tremor.

Supportive findings: Chronic tacrolimus use; however, pattern more often central (encephalopathy) than peripheral neuropathy.

- Nutritional/Metabolic Neuropathies:

Rationale: Prolonged illness may cause B12, folate, thiamine deficiencies; can cause axonal neuropathy.

Supportive findings: High risk due to malnutrition; needs lab confirmation.

- Post-Transplant Immune-Mediated Neuropathies:

Rationale: Chronic immunosuppression may predispose autoimmune neuropathies.

Supportive findings: Progressive sensory-motor neuropathy; requires CSF and immunologic evaluation.

- Infectious Neuropathies:

Rationale: Serratia bacteremia with disseminated infection; possibility of post-infectious or direct infectious neuropathy.

Supportive findings: Past severe infections; requires exclusion with CSF or serology if symptoms acute/subacute.

Recommended Ancillary Testing

To refine etiology and rule out treatable causes, the following investigations are recommended:

Electrodiagnostic Studies

Repeat EMG/NCS (including upper extremities) to document progression, demyelinating features, or multifocal involvement.

F-wave and H-reflex studies for proximal conduction block or radiculoplexopathy evaluation.

Laboratory Testing

Metabolic/Nutritional Panel: Vitamin B12, methylmalonic acid, folate, thiamine, copper, vitamin E.

Endocrine/Metabolic: Hemoglobin A1c, thyroid function, renal/hepatic function.

Inflammatory/Autoimmune Markers: ANA, ESR, CRP, ANCA, SSA/SSB, complement levels.

Paraneoplastic/Onconeural Antibodies: If asymmetric or multifocal features unexplained.

Infectious Serologies: HIV, syphilis, hepatitis panel, CMV/EBV if clinically indicated.

Cerebrospinal Fluid (CSF) Analysis

Evaluate for albuminocytologic dissociation (supportive of CIDP) or infectious/inflammatory markers.

Imaging

MRI Lumbosacral Plexus/Spine: Assess for structural or inflammatory plexopathy (e.g., ischemic, post-surgical scarring, hematoma, inflammatory infiltration).

MRI Brain/Spine if central involvement suspected.

Nerve or Skin Biopsy

Consider sural nerve or skin biopsy if diagnosis unclear after noninvasive workup; can differentiate vasculitic neuropathy, amyloidosis, or severe axonopathy.

Other Transplant-Related

Tacrolimus trough levels and neurotoxicity assessment.

9. Recommendations

Below is the point-by-point response incorporating functional medicine strategies alongside conventional recommendations. It addresses the member's request for education, treatment review, and additional options to discuss with local providers:

1. Understanding the Diagnosis and Associated Symptoms

The member's neuropathy arises from multiple factors—diabetes, ESRD/uremia, critical illness, and posttransplant complications—leading to severe chronic axonal sensorimotor polyneuropathy with lumbosacral plexopathy. Symptoms such as numbness, electric shocks, and burning sensations in the feet are consistent with this pattern. Functional medicine emphasizes identifying underlying drivers (glycemic variability, micronutrient deficits, chronic inflammation, mitochondrial dysfunction) and correcting them to support nerve repair and optimize recovery.

2. Review of Current Treatment Regimen

Gabapentin 200 mg nightly: Subtherapeutic; may require cautious titration or alternatives like pregabalin or duloxetine (doseadjusted for ESRD).
Immunosuppression (Tacrolimus, Prednisone): Essential for graft survival; functional medicine approach includes monitoring for neurotoxicity and mitigating steroid-induced nutrient depletion (e.g., vitamin D, magnesium, zinc).
Cardiovascular and renal medications: Continue carvedilol, valsartan, statins, and aspirin, monitoring for interactions and ensuring lipid and blood pressure optimization.

Supplements: Currently, vitamin D and multivitamins; assess adequacy and consider targeted nutrient repletion based on testing.

3. Additional Treatment Options

Conventional Approaches

Optimize neuropathic pain agents (gabapentinoids, duloxetine, topical lidocaine/capsaicin).

Resume physical and occupational therapy postfracture with focus on balance and strength.

Orthotic devices (AFO) for foot drop and fall prevention.

Consider interventional therapies (peripheral nerve or spinal cord stimulation) for refractory pain.

Functional Medicine Approaches

Antiinflammatory nutrition: Emphasize whole foods, lowglycemic diet rich in omega3s, antioxidants (berries, leafy greens), and avoidance of processed sugars.

Mitochondrial support: Coenzyme Q10 (100–300 mg/day), alphalipoic acid (300–600 mg BID), and acetylLcarnitine (500–1000 mg BID) to enhance nerve energy metabolism.

Neuroprotective botanicals: Curcumin (with piperine), Boswellia for neuroinflammation; Rhodiola for fatigue.

Glycemic and metabolic optimization: Continuous glucose monitoring and individualized nutritional counseling to maintain HbA1c in target range.

Gutimmune modulation: Evaluate for dysbiosis postantibiotics; consider probiotics and gutrepair strategies to reduce systemic inflammation.

Lifestyle interventions: Structured sleep hygiene, mindfulness for pain modulation, and graded activity programs tailored to mobility limits.

4. Ancillary Testing to Guide Care

Nutrient status: B12, methylmalonic acid, folate, thiamine, copper, zinc, vitamin E, vitamin D levels.

Inflammatory and metabolic markers: hsCRP, homocysteine, fasting insulin, omega3 index.

Autoimmune screen: ANA, SSA/SSB, ANCA, complements, antiMAG or antiganglioside antibodies if atypical features.

Advanced testing (if available in functional practice): Organic acids, oxidative stress markers, mitochondrial function panels.

Imaging and electrodiagnostics: Repeat EMG/NCS to track progression; MRI lumbosacral plexus to clarify plexopathy; autonomic testing if symptoms warrant.

CSF analysis: If immunemediated neuropathy suspected (CIDP or posttransplant immune neuropathy).

5. Next Steps to Discuss with Local Providers

Explore dose adjustment or switch of neuropathic agents for better symptom control.

Initiate nutritional repletion based on deficiencies (e.g., B12, thiamine, magnesium).

Begin antiinflammatory dietary plan with emphasis on glycemic control and nutrient density.
Plan rehabilitation timeline after ankle fracture; include balance and proprioceptive training.
Integrate functional medicine supplements (CoQ10, ALA, omega3s) if compatible with transplant medications and renal status.
Maintain close coordination with transplant, nephrology, and neurology teams to balance graft health and neuropathy management.

9. Member Questions & Answers:

Q1) Etiology/Mechanism

Which factors (diabetic, uremic, critical-illness, medication-related, and EMG-confirmed lumbosacral plexopathy) best explain his mixed pattern of length-dependent sensory loss and asymmetric proximal weakness, and how do they interact?

Detailed Answer

Multifactorial base:

Diabetic length-dependent axonal polyneuropathy → explains the distal, symmetric sensory loss and burning/electric pains in both feet.

Uremic neuropathy (ESRD on hemodialysis) → adds to the axonal, length-dependent picture and worsens sensory ataxia/areflexia.

Critical-illness polyneuropathy/myopathy (prolonged ICU, sepsis, ventilation) → contributes to global axonal loss and generalized weakness.

Superimposed focal process:

Right lumbosacral plexopathy on EMG (subacute→early chronic) → best explains the asymmetric proximal weakness (R>L) and functional decline out of proportion to the length-dependent pattern.

Possible modifiers (to check/monitor):

Tacrolimus neurotoxicity (less typical for length-dependent PN but possible): correlate symptoms with trough levels.

Nutritional deficits (thiamine, B12, copper, vitamin E) after critical illness and repeated hospitalizations.

Bottom line: The overall picture is a severe chronic axonal sensorimotor polyneuropathy (diabetes + ESRD + critical illness) compounded by a right lumbosacral plexopathy, which drives the asymmetry and proximal weakness; this combination, plus the left foot-drop and recent ankle fracture, explains the current mobility/fall risk.

The member should discuss with his providers:

Whether the EMG-confirmed right lumbosacral plexopathy changes near-term management (e.g., imaging, bracing, rehab load).

A plan to correlate symptoms with tacrolimus troughs and adjust dosing if neurotoxicity is suspected.

Timing of nutritional labs (B12/MMA, thiamine, copper, vitamin E) and targeted repletion.

Q2) Diagnostic Next Steps

What renal- and transplant-compatible tests should be prioritized now (e.g., repeat EMG/NCS with F-waves/H-reflex, MRI lumbosacral plexus, targeted nutritional/autoimmune labs, selective CSF if evolution suggests), and how will each result change management?

Detailed Answer

Now (0–2 weeks):

Repeat EMG/NCS (include upper limbs) with F-waves/H-reflex → document progression; better localize proximal involvement; refine rehab/DME requirements.

MRI neurography of the lumbosacral plexus ± lumbar spine (plexopathy protocol) → identify ischemic, inflammatory, or compressive etiologies that are treatable.

Targeted labs: B12, MMA, thiamine, copper, vitamin E, TSH, A1c, ESR/CRP; consider SSA/SSB, ANCA, complements if atypical features evolve.

Tacrolimus trough review (with symptom diary) → screen for exposure-related neurotoxicity.

Conditional (if course becomes atypical or rapidly progressive):

CSF analysis (protein, cell count; autoimmune/infectious panels) — only if new red flags or if EMG/MRI suggest an immune-mediated process.

Practical coordination: draw labs on non-dialysis days when possible; schedule PT after dialysis for energy; time MRI/EMG before major therapy changes.

The member should discuss with his providers:

Scheduling MRI LS plexus and repeat EMG/NCS with F/H within the next 0–2 weeks.

Which lab set to prioritize first (nutritional, autoimmune, inflammatory) and when given dialysis timing.

Criteria for proceeding to CSF (what red flags would trigger it).

Q3) Medication Optimization

Given subtherapeutic gabapentin, what is the safest, evidence-based analgesic strategy (e.g., pregabalin renal-adjusted, topical lidocaine/capsaicin, cautious/conditional duloxetine) and what monitoring is needed for side effects and tacrolimus interactions?

Detailed Answer

Stop relying on subtherapeutic gabapentin 200 mg qHS.

Switch to pregabalin (renal-adjusted):

Start 25–50 mg qHS, titrate every 7–14 days to effect/tolerability.

In hemodialysis, consider a post-dialysis supplemental 25–50 mg on HD days (confirm with nephrology).

Monitor edema, somnolence, BP, and dizziness (falls).

Topical analgesics (renal/transplant safe):

5% lidocaine patches to focal plantar/ankle pain (12 h on/12 h off).

8% capsaicin (clinic-based) for refractory focal allodynia.

Duloxetine: generally avoid in ESRD; if nephrology confirms it's acceptable, use very low dose with close Na+/BP monitoring; prefer pregabalin + topicals first.

Sleep–pain synergy: sleep hygiene + stimulus control; melatonin if needed; avoid sedatives on PT days.

If pain remains refractory despite the above and imaging excludes a treatable plexopathy → refer for peripheral nerve stimulation (PNS) or spinal cord stimulation (SCS) with transplant-ID peri-procedure precautions.

Continue immunosuppression per transplant; keep IVIG for hypogammaglobulinemia as directed by transplant team.

The member should discuss with his providers:

A pregabalin initiation/titration plan (dose, HD-day supplemental dosing, monitoring).

Adding lidocaine patches now and whether capsaicin 8% is appropriate for focal pain.

Whether duloxetine is contraindicated in his ESRD or could be trialed at very low dose under close monitoring.

Q4) Function & Safety

Which orthotics/DME (e.g., custom AFO, off-loading insoles) and PT/OT milestones (balance/proprioception, transfer training, dialysis-timed sessions) will most effectively reduce falls, protect skin integrity, and restore mobility after the ankle fracture?

Detailed Answer

Orthotics/DME:

Custom AFO (left) for foot-drop; off-loading insoles; wheelchair cushion; grab bars and shower chair for home safety.

Daily foot inspection (ulcer prevention) and podiatry follow-up.

PT/OT (dialysis-aware, staged):

Weeks 0–2: seated strengthening (hip/knee flexors), transfer training, core/proprioceptive work; home fall-proofing (rails, night lighting, remove loose rugs).

Weeks 3–6: standing frame and parallel bars as ortho permits; progress balance tasks; dose sessions after dialysis when possible.

Weeks 6–8: begin AFO-assisted gait training; task-specific balance and endurance; monitor orthostasis/fatigue.

By week 12: community-distance goals tailored to fracture recovery and strength gains.

Measurable targets (SMART):

Pain: ≥30% reduction on NRS by 8–12 weeks.

Function: safe stand-pivot transfers by week 6; ≥25% improvement on TUG or 10-meter walk by week 12.

Falls/Skin: 0 injurious falls; no new skin breakdown.

The member should discuss with his providers:

Immediate prescriptions for custom AFO, off-loading insoles, and home safety DME.

A PT schedule aligned with dialysis days and a written milestone plan (0–2, 3–6, 6–8, 12 weeks).

How to log falls/near-misses and skin checks for review at follow-ups.

Q5) Care Coordination & Follow-up

What multidisciplinary cadence (neurology, transplant, nephrology, PT/OT) and time-bound outcomes (pain, gait, falls, skin checks) should be used over the next 4–12 weeks, and which red-flags warrant urgent escalation (rapid asymmetry, sphincter changes, new wounds, systemic symptoms)?

Detailed Answer

Multidisciplinary cadence: monthly neuro–transplant–nephrology–PT/OT huddles until stable; message-based coordination for interim changes.

Follow-ups:

4–6 weeks: med response to pregabalin/topicals, PT progression, falls & skin log, tacrolimus trough review.

8–12 weeks: review EMG/MRI results, escalate/adjust rehab (AFO gait block), update SMART goals, decide on PNS/SCS if still refractory.

What we'll measure: pain scores, TUG/10-meter walk, number of near-misses/falls, skin integrity, orthostatic vitals, adherence to home program.

Red flags (urgent action):

Rapidly worsening asymmetric weakness, new sphincter dysfunction, acute severe back/leg pain, fever or wound drainage, sudden gait collapse, or signs of acute graft issue.

If present → ED/urgent imaging and immediate transplant–neuro–ID communication.

The member should discuss with his providers:

Setting up a standing monthly huddle (neuro, transplant, nephrology, PT/OT) and who coordinates it.

The exact 4–6 week and 8–12 week clinic dates and which metrics will be reviewed.

A clear ED plan for red flags (which hospital, who to page, what to bring).

10. Closing Statement

Thank you for seeking a second opinion and for sharing such detailed records—your engagement made this review precise and actionable.

Key takeaways

Your neuropathy is multifactorial (diabetes + ESRD/uremia + prior critical illness) with EMG-confirmed right lumbosacral plexopathy, explaining the length-dependent distal sensory loss plus asymmetric proximal weakness. The recent ankle fracture and foot-drop markedly increase fall risk.

Most impactful next steps (0–2 weeks): repeat EMG/NCS with F-waves/H-reflex, obtain MRI neurography of the lumbosacral plexus (± lumbar spine), and draw targeted labs (B12/MMA,

thiamine, copper, vitamin E; ESR/CRP; ± autoimmune markers as indicated). Correlate tacrolimus troughs with symptom changes.

Pain/medications: transition from subtherapeutic gabapentin 200 mg qHS to renal-adjusted pregabalin and add topical lidocaine (± clinic 8% capsaicin). Avoid duloxetine in ESRD unless nephrology approves a very low-dose trial with close monitoring.

Function & safety: prescribe a custom AFO, off-loading insoles, and home-safety DME; restart dialysis-aware PT/OT with staged milestones and logs for falls/near-misses and skin checks.

Goals & cadence: SMART targets include ≥30% pain reduction by 8–12 weeks, safe stand-pivot transfers by week 6, and AFO-assisted gait initiation by week 8 (orthopedic clearance permitting). Follow-ups at 4–6 weeks (med/rehab response, trough review) and 8–12 weeks (test results, plan update).

Care coordination: monthly huddles among neurology, transplant, nephrology, and PT/OT until stable.

Red flags: rapidly worsening asymmetric weakness, new sphincter dysfunction, acute severe back/leg pain, fever or wound drainage, or sudden gait collapse → seek urgent care/ED and notify transplant and neurology teams.

Please share this report

Kindly share this summary and the full second-opinion note with your treating providers—especially your transplant cardiology, nephrology, neurology, orthopedics, PM&R, and PT/OT teams. You can copy/paste into your patient portal message or provide them a PDF. If helpful, you may also authorize me to coordinate directly with your clinicians to align testing, medication adjustments, and rehabilitation timing.

Collaborative care & implementation

These recommendations are intended to support (not replace) your ongoing care. Before making any changes, review testing, medications, orthotic/DME orders, and therapy plans with your treating clinicians—particularly transplant and nephrology—to keep everything graft-safe and renal-appropriate. I'm happy to connect with your care team to finalize the plan and monitoring.

Electronically Signed:

Dr. Nizar Souayah, MD, FAAN, FAANEM, FANA

Triple Board-Certified Neurologist

Neuromuscular & Electrodiagnostic Medicine Specialist